

Patent

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Donald H. Burns, et al.

Int'l Appln.  
No. : PCT/US03/29707

Int'l Date  
Filed : 19 September 2003 (19/09/2003)

Serial No. : (To be assigned) Case No.: 21232YP

Filed : March 23, 2005

For : RADIOLABELED NEUROKININ-1 RECEPTOR  
ANTAGONISTS

Commissioner for Patents  
Alexandria, Virginia 22313-1450

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR § 1.97**

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

**EXPRESS MAIL CERTIFICATE**

DATE OF DEPOSIT 3/23/05

EXPRESS MAIL NO. EL989587575 US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS  
BEING DEPOSITED WITH THE UNITED STATES POSTAL  
SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"  
ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO  
COMMISSIONER FOR PATENTS, P.O. BOX 1450,  
ALEXANDRIA, VIRGINIA 22313-1450.

MAILED BY [Signature]

DATE 3/23/05

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.


In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.98(a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application are not enclosed herewith. Copies of the other references that are cited on the attached form PTO-1449 are enclosed herewith.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By   
J. Eric Thies  
Reg. No. 35,382  
Attorney for Applicant

MERCK & CO., Inc.  
P.O. Box 2000  
Rahway, New Jersey 07065-0907  
(732) 594-3904

Date: March 23, 2005

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE**  
**STATEMENT BY APPLICANT**

*(use as many sheets as necessary)*

**COMPLETELY KNOWN**

**Application Number****Filing Date**

March 4, 2005

**First Named Inventor**

Doanld H. Burns et al

### Group Art Unit

**Examiner Name**

Attorney Docket Number

21232YP

U.S. PATENT DOCUMENTSExaminer  
Initials\*Cite  
No.

U.S. Patent Document

Number

Kind  
Code  
(if known)Name of Patentee or Applicant  
of Cited Document

Date of Publication of  
Cited Document  
MM-DD-YYYY

US 6,241,964

Burns et al

06/05/2001

## FOREIGN PATENT DOCUMENTS

Examiner  
Initials\*Cite  
No.

Foreign Patent Document

Office

Number

Kind  
Code  
(if known)Name of Patentee or Applicant  
of Cited Document

Date of Publication of  
Cited Document  
MM-DD-YYYY

WO 96/21661

**GLAXO GROUP LIMITED**

07/18/1996
------------

Examiner  
Signature

Date  
Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

[illegible]

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003